AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway

作者：Wang, Shu-Wei; Hu, Jun; Guo, Qin-Hao; Zhao, Yan; Cheng, Jie-Jing; Zhang, Dong-Sheng; Fei, Qiang; Li, Juan; Sun, Yue-Ming^*

来源：Oncology Reports, 2014, 32(5): 1991-1998.

DOI：10.3892/or.2014.3477

• interleukin-6
• AZD1480
• colorectal cancer
• Janus kinase 2
• signal transducer and activator of transcription 3
• therapeutic agent

Interleukin (IL)-6 and the downstream Janus kinase (JAK)/signal activator of transcription (STAT) pathway have been found to be important in the development of colorectal cancer (CRC). To develop novel therapies for CRC, we have explored the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK/STAT3 pathway and its potential antitumor activity on the human CRC cell lines (HCT116, HT29 and SW480). The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells. The inhibition of tumorigenesis was consistent with the decreased phosphorylated JAK2 and phosphorylated STAT3, and the decreased expression of STAT3-targeted genes c-Myc, cyclin D2 and IL-6. Thus, AZD1480 is a potential new clinical therapeutic agent for patients with CRC.

• 出版日期2014-11
• 单位南京医科大学